Pathophysiological and pharmacological relevance of TLR4 in peripheral immune cells after stroke

Pharmacol Ther. 2021 Dec:228:107933. doi: 10.1016/j.pharmthera.2021.107933. Epub 2021 Jun 24.

Abstract

Stroke is a very common disease being the leading cause of death and disability worldwide. The immune response subsequent to an ischemic stroke is a crucial factor in its physiopathology and outcome. This response is not limited to the injury site. In fact, the immune response to the ischemic process mobilizes mainly circulating cells which upon activation will be recruited to the injury site. When a stroke occurs, molecules that are usually retained inside the cell bodies are released into the extracellular space by uncontrolled cell death. These molecules can bind to the Toll-like receptor 4 (TLR4) in circulating immune cells which are then activated, eliciting, although not exclusively, the inflammatory response to the stroke. In this review, we present an up-to-date summary of the role of the different peripheral immune cells in stroke as well as the role of TLR4 in the function of each cell type in ischemia. Also, we summarize the different antagonists developed against TLR4 and their potential as a pharmacological tool for stroke treatment.

Trial registration: ClinicalTrials.gov NCT04742062 NCT04734548.

Keywords: Immune cells; Inflammation; Ischemic stroke; Stroke; TLR4.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Immunity
  • Stroke* / drug therapy
  • Stroke* / immunology
  • Stroke* / physiopathology
  • Toll-Like Receptor 4* / immunology
  • Toll-Like Receptor 4* / physiology

Substances

  • Toll-Like Receptor 4

Associated data

  • ClinicalTrials.gov/NCT04742062
  • ClinicalTrials.gov/NCT04734548